NADH-ubiquinone oxidoreductase 11 kDa subunit Antibody

What is the NADH-ubiquinone oxidoreductase 11 kDa subunit and what is its role in Complex I?

The NADH-ubiquinone oxidoreductase 11 kDa subunit (often referred to as NDUFA2) is an accessory subunit of mitochondrial Complex I (NADH:ubiquinone oxidoreductase). Complex I is a massive protein assembly of approximately 950,000 Da molecular weight composed of 45-46 different subunits that catalyzes electron entry from NADH via flavin (FMN) and several non-heme iron centers . While NDUFA2 is not directly involved in catalysis, it plays a crucial role in the proper assembly and structural integrity of Complex I. The protein has a calculated molecular weight of 11 kDa (99 amino acids) and is encoded by the NDUFA2 gene (Gene ID: 4695) . This subunit serves as part of the electron transport chain that is essential for generating the proton-motive force necessary for ATP synthesis, directly linking it to cellular energy metabolism .

How are NADH-ubiquinone oxidoreductase 11 kDa subunit antibodies typically produced and validated?

These antibodies are typically generated using recombinant NDUFA2 fusion proteins as immunogens. For example, commercially available polyclonal antibodies are commonly produced in rabbits immunized with NDUFA2 fusion proteins . Validation of these antibodies includes:

• Western blot analysis confirming detection of a band at approximately 11 kDa in appropriate tissues (particularly heart and liver tissues from multiple species)

• Immunohistochemistry verification in tissues with high mitochondrial content

• Testing across multiple species to confirm cross-reactivity (typically human, mouse, and rat samples)

• Knockout/knockdown validation to confirm specificity

NDUFA2 antibodies require careful validation as the small size of the protein can sometimes make it challenging to detect, and specificity must be confirmed to avoid cross-reactivity with other Complex I subunits.

What are the optimal applications for NADH-ubiquinone oxidoreductase 11 kDa subunit antibodies?

Based on validation data, NDUFA2 antibodies demonstrate high utility in several experimental applications:

For optimal results in Western blotting, tissues with high mitochondrial content such as heart, liver, and kidney generally yield the strongest signals . When performing IHC, antigen retrieval with TE buffer (pH 9.0) is recommended, though citrate buffer (pH 6.0) may serve as an alternative . The application-specific dilution should be titrated for each experimental system to obtain optimal results.

How should researchers design experiments to measure Complex I activity in conjunction with antibody-based detection methods?

A methodologically sound approach integrates antibody-based detection with functional assays:

• Protein expression analysis: Use Western blotting with NDUFA2 antibodies at 1:1000-1:4000 dilution to assess protein levels in cell/tissue lysates .

• Complex I activity measurement: Implement a spectrophotometric assay monitoring NADH oxidation at 340 nm. The protocol involves:

  • Cell lysis and isolation of mitochondria through differential centrifugation

  • Resuspension of mitochondrial pellet in appropriate buffer solution

  • Reaction setup with sample, buffer components, and measurement of absorbance at 340 nm

  • Activity calculation using the formula: Complex I activity (U/mg protein) = [ΔA × Vsum ÷ (ε × d) × 10^9] ÷ (Vsample × Cpr) ÷ T

• Correlation analysis: Compare protein levels detected via antibodies with enzymatic activity to establish structure-function relationships.

This integrated approach provides more meaningful data than either technique alone, allowing researchers to associate changes in Complex I subunit expression with functional outcomes.

How can researchers optimize protein extraction to ensure reliable detection of the 11 kDa subunit?

The small size and hydrophobic nature of NDUFA2 can present challenges for extraction and detection. Optimize your protocol with these methodological considerations:

• Extraction buffer composition: Use radioimmunoprecipitation assay (RIPA) buffer containing protease inhibitors (e.g., phenylmethylsulfonyl fluoride) for efficient extraction while preserving protein integrity .

• Extraction conditions: Perform extraction at 4°C for 30 minutes followed by centrifugation at 13,000 rpm for 15 minutes .

• Protein denaturation: Thoroughly denature samples by boiling in SDS-loading buffer to ensure complete solubilization of the membrane-associated protein.

• Gel selection: Use high-percentage (15-18%) polyacrylamide gels or gradient gels to properly resolve this small protein.

• Transfer optimization: Implement wet transfer using low molecular weight-optimized conditions (higher methanol content) when transferring to PVDF membranes (0.45 μm) .

• Blocking conditions: Block membranes with 5% nonfat powdered milk for 1.5 hours before antibody incubation .

Following these methodological steps will significantly improve detection sensitivity and specificity for this challenging protein target.

What are common pitfalls in antibody applications for NDUFA2 and how can they be addressed?

Several technical challenges can arise when working with NDUFA2 antibodies:

Additional guidance: For IHC applications, optimize fixation time as overfixation can mask epitopes, particularly for small mitochondrial proteins. When interpreting results, consider using multiple antibodies targeting different Complex I subunits as internal controls for mitochondrial integrity.

How can NDUFA2 antibodies be used to investigate Complex I dysfunction in disease models?

Complex I dysfunction contributes to various pathological conditions including neurodegenerative disorders, cancer, and metabolic diseases. NDUFA2 antibodies provide valuable tools for investigating these relationships:

• Neurodegenerative disease research: Use NDUFA2 antibodies to assess Complex I integrity in Parkinson's disease models, where Complex I dysfunction is implicated in pathogenesis . Combine with functional assays to correlate structural alterations with bioenergetic deficits.

• Cancer metabolism studies: Implement NDUFA2 immunodetection to evaluate alterations in mitochondrial function in cancer cells. Evidence suggests hepatocellular carcinoma cells downregulate components of Complex I, potentially as a metabolic adaptation . This approach can reveal mechanisms underlying the Warburg effect.

• Diabetes investigations: Assess NDUFA2 expression patterns in diabetic tissue samples, as Complex I involvement in diabetes has been documented . Compare expression levels between healthy and pathological samples to identify potential therapeutic targets.

• Toxicology research: Utilize NDUFA2 antibodies to evaluate the impact of environmental toxins on mitochondrial integrity, as Complex I is sensitive to many inhibitors including pesticides and common environmental toxins like rotenone .

For meaningful insights, integrate antibody-based detection with functional assays measuring oxygen consumption, ROS production, and ATP synthesis to establish mechanistic relationships between structural alterations and bioenergetic consequences.

What methodological approaches enable the study of NDUFA2 interactions with other Complex I subunits?

Understanding subunit interactions within Complex I requires sophisticated technical approaches:

• Co-immunoprecipitation (Co-IP): Use NDUFA2 antibodies for Co-IP followed by mass spectrometry to identify interaction partners. This approach can reveal both stable and transient protein-protein interactions within the complex.

• Proximity labeling: Employ techniques like BioID or APEX2 where NDUFA2 is fused to a promiscuous biotin ligase to identify proteins in close proximity within the native cellular environment.

• Super-resolution microscopy: Combine NDUFA2 antibodies with antibodies against other Complex I subunits for multi-color super-resolution microscopy to visualize spatial relationships between subunits at nanometer resolution.

• Crosslinking mass spectrometry (XL-MS): Apply protein crosslinking followed by mass spectrometry to capture direct interaction interfaces between NDUFA2 and other Complex I components.

• Blue native PAGE: Use non-denaturing gel electrophoresis followed by Western blotting with NDUFA2 antibodies to analyze intact Complex I assembly and subcomplexes.

These approaches can reveal how NDUFA2 contributes to Complex I assembly, stability, and function, providing insights into the complex architecture and potential vulnerability points in disease states.

How are NDUFA2 antibodies being used to investigate mitochondrial dynamics and quality control?

Emerging research is employing NDUFA2 antibodies to explore the relationship between Complex I and broader mitochondrial processes:

• Mitophagy assessment: Use NDUFA2 immunofluorescence co-localized with autophagy markers to track selective degradation of damaged mitochondria containing dysfunctional Complex I.

• Mitochondrial biogenesis: Implement NDUFA2 antibodies to monitor the incorporation of newly synthesized subunits into Complex I during mitochondrial biogenesis, providing insights into assembly pathways.

• Stress response dynamics: Apply NDUFA2 immunodetection to investigate how oxidative stress affects Complex I integrity and turnover, revealing adaptive mechanisms to maintain mitochondrial function.

This research direction requires integrating NDUFA2 antibody-based detection with dynamic live-cell imaging techniques and functional metabolic assays to provide a comprehensive view of mitochondrial adaptation to cellular stressors.

What methodological considerations are important when using NDUFA2 antibodies in studies of post-translational modifications?

Post-translational modifications (PTMs) of Complex I subunits can significantly impact function. When investigating PTMs of NDUFA2:

• Sample preparation: Preserve PTMs by using phosphatase inhibitors, deacetylase inhibitors, and protease inhibitors during extraction .

• Modification-specific antibodies: When available, use antibodies specifically recognizing phosphorylated, acetylated, or otherwise modified NDUFA2.

• IP-MS approach: Perform immunoprecipitation with NDUFA2 antibodies followed by mass spectrometry analysis to comprehensively identify PTMs.

• Validation with site-directed mutagenesis: Confirm the functional significance of identified PTMs by expressing mutant forms of NDUFA2 where modification sites are altered.

• Contextual analysis: Evaluate how cellular stressors, signaling pathways, or disease states affect the PTM profile of NDUFA2 to establish regulatory mechanisms.

This approach can reveal how PTMs regulate Complex I activity and contribute to adaptive responses under various physiological and pathological conditions.